Postby DK37 » Sun Jun 05, 2016 7:27 am
The Y-axis is "survival" OS = overall survival (i.e. death). PFS = survival until time that cancer comes back resistant. You want the Y-axis as high as possible. X-axis is time in months. You want that to be as long as possible. So ideally you want a flat line going from the top of the Y-axis all the way across (100% of patients living without issue for length of study). You'll see from line color coding that adding Yervoy bumps the lines higher on Y-axis meaning more patients responded. Impacts on the length of response data is still in progress. So in a nutshell, so far it looks like the combo data is better than PD1 monotherapy in MSI-high patients.
-DK
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
7/12 FOLFOX/FOLFIRI
2/13 NED!
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
3/15 Cetuximab
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)
MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List